Karyopharm Therapeutics (KPTI) Operating Income (2012 - 2025)

Karyopharm Therapeutics has reported Operating Income for 14 years, with the latest figure at $31.7 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Income rose 201.35% year-over-year to $31.7 million; the trailing twelve-month figure through Dec 2025 stood at -$41.2 million (up 65.54% YoY), and the FY2025 full-year result was -$41.2 million, up 65.54% from the prior year.
• Operating Income for Q4 2025 stood at $31.7 million, up from -$15.2 million in the prior quarter.
• The five-year high for Operating Income was $47.0 million in Q4 2021, with the low at -$52.4 million in Q1 2021.
• Historically, Operating Income has averaged -$26.5 million across 5 years, with a median of -$31.3 million in 2023.
• Annual changes were most pronounced in 2021 — Operating Income jumped 226.7% — and 2022, when it plunged 172.12%.
• Karyopharm Therapeutics' Operating Income stood at $47.0 million in 2021, then tumbled by 172.12% to -$33.9 million in 2022, then dropped by 11.63% to -$37.8 million in 2023, then increased by 17.26% to -$31.3 million in 2024, then soared by 201.35% to $31.7 million in 2025.
• The last three Operating Income figures came in at $31.7 million (Q4 2025), -$15.2 million (Q3 2025), and -$24.4 million (Q2 2025), per Business Quant data.